Response to: 'Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors' by Jovani et al

Ann Rheum Dis. 2022 Jul;81(7):e132. doi: 10.1136/annrheumdis-2020-218179. Epub 2020 Jun 25.
No abstract available

Keywords: antirheumatic agents; autoimmune diseases; epidemiology.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Letter
  • Comment

MeSH terms

  • Antirheumatic Agents* / therapeutic use
  • Biological Products* / therapeutic use
  • COVID-19*
  • Humans
  • Incidence
  • Janus Kinase Inhibitors* / therapeutic use
  • Rheumatic Diseases* / chemically induced
  • Rheumatic Diseases* / drug therapy
  • Rheumatic Diseases* / epidemiology

Substances

  • Antirheumatic Agents
  • Biological Products
  • Janus Kinase Inhibitors